Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Xaroban vs Xarelto (Rivaroxaban) in Healthy Pakistani Males
NCT04689919Phase 1Completed
- Sponsor
- University of Karachi
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolism (2 arms), sponsored by University of Karachi. Primary endpoints: Peak Plasma Concentration at 2 weeks, Area under the plasma concentration versus time curve 0-t at 2 weeks and 1 more. Started Feb 2022; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04689919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689919.